MERZ-THERAPEUTICS
31.8.2021 13:06:13 CEST | Business Wire | Press release
Today, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, has been granted the use of XEOMIN® for the symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg of chronic sialorrhea due to neurological / neurodevelopmental disorders on EU level.1 The national approvals of the country authorities involved will follow in the next weeks. The U.S. Food and Drug Administration granted approval in December 2020, and the Russian Federal Service for Surveillance in Healthcare in spring 2021.
Stefan Brinkmann, CEO Merz Therapeutics: “At Merz Therapeutics, we do everything to bring better outcomes to more patients. As XEOMIN® is already approved for the treatment of adult sialorrhea, we can now offer life-long treatment with our botulinum toxin A, staying a trusted partner for sialorrhea patients as well as their relatives and physicians for a lifetime.”
Dr. Marcus Gollub, President, Head of Region Europe complements: “Pediatric sialorrhea is a serious condition that can significantly impact not only the medical condition but also the quality of life of the children and their families. I am happy that with this new indication we are able to take care of the needs of those children suffering from drooling and contribute to a better life for them and their families.”
Sialorrhea, also known as drooling, is a symptom that occurs when excessive saliva accumulates in the mouth. It is a chronic impairment often seen in children with neurological disorders (e.g. cerebral palsy or traumatic brain injury) and/or intellectual disability or neurodegenerative diseases.
The approval by European authorities for the use of XEOMIN® for pediatric patients suffering from chronic sialorrhea, was achieved due to the convincing results of the SIPEXI study (Si alorrhea Pe diatric X eomin I nvestigation). It was a prospective, randomized, double-blind, placebo-controlled, multicenter phase III study with an extension phase evaluating the safety and efficacy of XEOMIN® in 255 children and adolescents aged 2 – 17 years up to 64 weeks. The study recently got published in Neurology, the premier peer-reviewed journal for clinical neurology research.2
XEOMIN® is being distributed by Merz Pharmaceuticals GmbH in more than 70 countries to treat patients with upper and lower limb spasticity, cervical dystonia, blepharospasm or hypersalivation. Merz uses state-of-the-art technology in its dedicated facility in Dessau, Germany, meeting the highest international standards for biologic manufacturing. The highly purified 150kDa neurotoxin is the only active ingredient in XEOMIN® . It is produced by removing complexing proteins from botulinum toxin type A, using XTRACT® purification technology developed by Merz Pharma GmbH & Co. KGaA.
XEOMIN® is the registered trademark of Merz Pharma GmbH & Co. KGaA.
1
European SmPC (Summary of product characteristics), 2021-08-31
2
Berweck et al. Neurology. 2021 Aug 2:10.1212/WNL.0000000000012573. doi: 10.1212/WNL.0000000000012573.
About Merz Therapeutics
Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that meet patient and customer needs.
Please visit www.merz.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005540/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
INNIO Secures 450 MW Order to Power Next-Generation Data Centers17.9.2026 14:30:00 CEST | Press release
U.S. based energy company orders Jenbacher J624 containerized engines to support deployment of fast-track, behind-the-meter power solutions for large-scale data centers 450 MW firm order booked in Q3 2026 INNIO N.V. (Nasdaq: INIO) today announced it has secured an order from a U.S. energy company for 450 megawatts (MW) of power infrastructure. INNIO's Jenbacher J624 containerized gas engines will support the deployment of prime power solutions for large-scale data center projects in North America. The order reflects continued demand for the company's high-efficiency gas engine technology as data center developers seek off-grid alternatives to constrained grid infrastructure. This is the first order by the customer of this scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917646026/en/ INNIO secures 450 MW order to power next-generation data centers The engines are expected to be delivered by 2028. The firm order was b
Adtran showcases open optical networking for AI infrastructure at OIF’s ECOC 2026 interop demo17.9.2026 14:00:00 CEST | Press release
News summary: Open optical ecosystems give operators greater flexibility and vendor choice as they scale networks for the AI era Adtran’s pluggable coherent ZR+ transceivers, FSP 3000 OLS and Mosaic Network Controller key to open transport and hierarchical control in OIF demo Adtran also hosted the OIF test run in its system integration labs in Gdynia, Poland, helping to ensure the demo’s success at the show Adtran today announced its participation in OIF’s live multi-vendor interoperability demo at ECOC 2026, taking place September 21 to 23 in Málaga, Spain. Bringing together 39 member companies, the showcase highlights interoperable optical transport, pluggable coherent transceivers and network control technologies in a multi-vendor environment. Adtran is contributing 100Gbit/s, 400Gbit/s and 800Gbit/s ZR+ pluggables, its FSP 3000 open line system (OLS) operating across C- and L-bands and Mosaic Network Controller software. Ahead of the event, Adtran also hosted the OIF test run in G
IFF Launches Omni-Bos™ PHY to Help Dairy Producers Get More Value from Feed17.9.2026 13:00:00 CEST | Press release
New phytase technology unlocks nutrients already present in feed to improve efficiency, profitability and sustainability IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — today announced the launch of Omni-Bos™ PHY, a novel phytase enzyme designed specifically for dairy cattle. The technology helps producers improve nutrient utilization and feed efficiency by unlocking nutrients already present in feed, enabling cows to derive greater value from existing feed ingredients. Omni-Bos™ PHY will initially launch in the Middle East, Africa and Asia-Pacific regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916599752/en/ IFF has launched Omni-Bos™ PHY, a phytase enzyme developed specifically for dairy cattle, that helps producers unlock nutrients already present in feed to improve nutrient utilization and feed efficiency. “We believe the future of dairy nutrition is helping cows receive m
EdgeConneX Appoints SVP of Global Construction Delivery, Vice Presidents for Norway and Germany17.9.2026 13:00:00 CEST | Press release
New leaders to drive customer delivery and success, market development and growth, and community engagement EdgeConneX®, a global leader in Build-to-Suit and Build-to-Density digital infrastructure solutions, today announced the appointments of Garry O’Leary as SVP, Delivery, Global, Anders Hilt as Vice President of Norway, and Michael Barth as Vice President of Germany. All three hires bring a deep commitment to building strong local relationships and will play a key role in advancing the company's global projects and supporting community engagement and local support efforts. EdgeConneX continues to expand its platform globally, with gigawatts of major projects underway across multiple continents. As SVP, Delivery, Global, Garry plays a critical role in delivering the company's new capacity on time and on budget, overseeing regional construction leadership, contractor and vendor management, site safety, quality assurance, and supply chain. Prior to joining EdgeConneX, Garry was Vice P
Brushing Well Is Harder Than Most People Think — New Research Confirms Why the Technology Behind Oral-B iO is the Best Way to Help You Get it Right17.9.2026 12:40:00 CEST | Press release
Ranked #1 for plaque removal and gingivitis reduction, Oral-B iO's oscillating-rotating technology, paired with its unique round brush head, delivers a superior clean that helps people brush better every day, remove more plaque, and improve their gum health for healthier teeth for life. Oral-B, the #1 toothbrush brand used and recommended by dentists worldwide, today announced new evidence reinforcing the superiority of Oral-B iO technology. In an independent 2026 peer-reviewed network meta-analysis of 19 randomized clinical studies involving more than 1,300 participants, the oscillating-rotating technology behind Oral-B iO was ranked #1 for plaque removal and gingivitis reduction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260911054017/en/ Oral-B iO9 makes a superior clean easier to achieve every day. Most people think they are brushing effectively, but brushing well is harder than it seems. Plaque often remains in the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom